AI Summary & Key Takeaways
AI InsightBoth therapies were effective in reducing the LVH; Valsartan proved to be superior to Nebivolol in reducing the QT interval indexes in relation to blood pressure and LVM reduction.
📌 3 Key Takeaways
Abstract
Objectives: The aim of this study was to analyze the antihypertensive effect of Valsartan and Nebivolol and their effects on QT dispersion and left ventricular hypertrophy (LVH) in the treatment of naive hypertensive patients. Methods: A prospective study with a six-month follow-up was conducted on hypertensive patients with LVH and mild/ moderate essential hypertension. The patients were randomly assigned to Valsartan (80 to 160 mg/day) or Nebivolol (5 to 10 mg/day) groups. The study group consisted of 108 patients, 55 in the Valsartan group and 53 in the Nebivolol group. Results: The range of mean systolic blood pressure (SBP) varied from 152±17 (baseline) to 132±17 mmHg (follow-up) in the Valsartan group (p<0.001); from 146±13 to 125±14 mmHg in the Nebivolol group (p<0.001). The decrease in mean diastolic blood pressure (DBP) was 9.5±2.5 mmHg in the Valsartan group and 12.3±5.0 mmHg in the Nebivolol group. A signifcant reduction in QT and corrected QT (Bazett’s formula) dispersion was observed in both groups, with a slightly higher reduction in the Valsartan group. Echocardiography showed a de- crease in the left ventricle mass (LVM) indices (p<0.05) in both groups with a greater reduction in the Valsartan group. Conclusion: Valsartan treatment was as effective as Nebivolol in reducing the 24 hour- SBP after a 6 month treatment. Nebivolol treatment proved to be superior to Valsartan in reducing DBP. Both therapies were effective in reducing the LVH; Valsartan proved to be superior to Nebivolol in reducing the QT interval indexes in relation to blood pressure and LVM reduction.
Özet
Amaç: Bu çalışmanın amacı valsartan ve nebivololun antihipertansif etkilerini ve bu ilaçların hipertansif hastaların tedavisinde QT dağılımı ve sol ventrikül hipertrofsi üzerine etkilerini analiz etmektir. Yöntemler: Sol ventrikül hipertrofsi (SVH) bulunan haff/orta hipertansiyonlu hastalarda 6 ay süreli takip içeren prospektif bir çalışma düzenlendi. Hastalar rastgele olarak Valsartan (80-160 mg/gün) veya Nebivolol (5-10 mg/gün) gruplarına alındı. Çalışma grubu 55’i Valsartan grubu, 53’ü Nebivolol grubunda olmak üzere toplam 108 hastadan oluşturuldu. Bulgular: Valsartan grubunda ortalama sistolik kan basıncı (SKB) 152±17 mmHg (bazal)’den 132±17 mmHg (takip)’e değişti (p<0.001). Nebivolol grubunda ise ortalama SKB, 146±13 mmHg (bazal)’den 125±14 mmHg (takip)’e değişti (p<0.001). Valsartan grubunda ortalama diyastolik kan basıncı (DBP) azalması 9.5±2.5 mmHg ve Nebivolol grubunda 12.3±5.0 mmHg idi. Her iki grupta da QT ve düzeltilmiş QT (Bazett formülü) dağılımında anlamlı azalma gözlendi ve bu azalma Valsartan grubunda haffçe daha fazla idi. Ekokardiyograf sol venrikül kitle (SVK) indekslerinde Valsartan grubunda daha fazla azalma ile birlikte her iki grupta azalmayı gösterdi (p<0.05). Sonuç: Valsartan tedavisi 24 saatlik SKB’ında 6 aylık tedavi ile Nebivolol kadar etkili bulundu. Nebivolol tedavisi DKB’ını düşürmede Valsartan tedavisine üstün bulundu. Her iki tedavi SVH’sini azaltmada etkili idi. Valsartan kan basıncı ve SVK’de azalmayla birlikte QT aralık indekslerinde azaltmada Nebivolole üstün bulundu.